Dyne Therapeutics, Inc.

What they do

Dyne Therapeutics uses its proprietary FORCE platform to design and develop product candidates for neuromuscular diseases, including Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), facioscapulohumeral dystrophy (FSHD), and Pompe disease. The platform leverages a transferrin receptor 1 (TfR1)-targeting Fab to deliver oligonucleotide or enzyme payloads to muscle and CNS tissue. Lead candidates include z-rostudirsen (DYNE-251) for exon 51 skipping DMD and z-basivarsen (DYNE-101) for DM1, both in Phase 1/2/3 development.

Revenue drivers

• Z-rostudirsen (DYNE-251) for DMD exon 51 skipping — Lead product candidate; BLA accepted for priority review with PDUFA date January 21, 2027; potential US launch in Q1 2027; no revenue yet.
• Z-basivarsen (DYNE-101) for DM1 — Phase 1/2 ACHIEVE trial enrollment complete; topline data expected Q1 2027; potential BLA submission in Q3 2027; no revenue yet.
• Earlier-stage pipeline (DYNE-253, DYNE-245, DYNE-244, DYNE-255, DYNE-302) — Preclinical/IND-enabling candidates for DMD exons 53, 45, 44, 55, and FSHD; no revenue, potential future value.

Recent performance

For Q2 2026, the company reported cash and equivalents of $676.1M and total assets of $994.0M as of June 30, 2026, with shareholder equity of $702.2M and long-term debt of $199.3M. Year-to-date operating cash flow was not provided, but full-year 2025 net loss was $-446.2M with operating cash outflow of $-403.2M. The FDA accepted the z-rostudirsen BLA in July 2026 with priority review; enrollment of 71 participants in the ACHIEVE registrational cohort completed in June 2026.

Strategy

Management is executing on a registrational pathway for z-rostudirsen, targeting US Accelerated Approval and launch in Q1 2027. They are also advancing z-basivarsen with a confirmatory Phase 3 HARMONIA trial initiated in July 2026 and a planned BLA submission in Q3 2027. The company is expanding its pipeline with IND clearance for DYNE-302 in FSHD and plans to initiate a Phase 1 trial. They are investing in commercial capabilities to support a potential launch and expect cash runway into Q2 2028.

Risks

• Regulatory and approval risk — Approvals depend on FDA acceptance of BLA, priority review, and clinical data; any delay or negative outcome could impact launch timelines.
• Clinical trial risk — Phase 3 trials (FORZETTO, HARMONIA) may fail to meet endpoints or show safety issues, affecting approval and commercial viability.
• Commercial execution risk — As a clinical-stage company, it has no marketed products or revenue; first launch in Q1 2027 depends on manufacturing, payer coverage, and market acceptance.
• Financial risk — Net losses and negative operating cash flow are increasing (net loss of $-446.2M in 2025), and cash runway into Q2 2028 may be insufficient if timelines slip or costs rise.

Outlook

Management expects FDA decision on z-rostudirsen by January 21, 2027, with potential US launch in Q1 2027. For z-basivarsen, topline data from ACHIEVE REC is planned for Q1 2027, with BLA submission in Q3 2027 and potential launch in H1 2028. They also anticipate initiating a Phase 1 trial for DYNE-302 in FSHD and expect cash runway into Q2 2028.